SLC5A2 and diabetes mellitus: In the CVOT for empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor to treat diabetes, a neutral HR of 1.02 (0.81; 1.28) was observed in Europe, the largest participating region, whereas the HR for the total trial population was 0.86 (0.74; 0.99) (15).